RBC Capital Maintains Outperform on Biogen, Raises Price Target to $222

Benzinga Newsdesk www.benzinga.com Positive 86.3%

Neg 0% Neu 0% Pos 86.3%

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $213 to $222.